Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
तुलना करने के लिए मीट्रिक्स | RNTX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधRNTXपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.8x | −3.2x | −0.5x | |
PEG अनुपात | 0.32 | 0.00 | 0.00 | |
क़ीमत/बुक | 5.5x | 1.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 26.1x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 211.8% | 239.8% | 51.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | −0.5% | 9.5% | अनलॉक करें |